Table 4.
Survivorship of different TKA prosthesis designs
| TKA design | Years | Number* | Mean followup years/(range) | At 5 years** (95% CI) | At 10 years** (95% CI) | At 15 years** (95% CI) | HR (95% CI) | p value |
|---|---|---|---|---|---|---|---|---|
| Duracon™ | 1992–2011 | 990/18199 | 8.5 (0–19) | 96.4 (96.1,96.7) | 94.4 (94.0,94.7) | 91.9 (91.5,92.3) | 1.0 | – |
| PFC®
Sigma® |
1989–2011 | 590/13292 | 6.2 (0–22) | 96.8 (96.4,97.1) | 94.8 (94.4,95.2) | 88.9 (88.3,89.4) | 1.1 (1.0–1.2) | 0.24 |
| Miller-Galante II | 1989–1998 | 111/1008 | 11.5 (0–20) | 95.5 (94.0,96.7) | 90.8 (88.8,92.4) | 86.9 (84.7,88.9) | 1.5 (1.2–1.8) | < 0.001 |
| PCA®/ modular | 1985–1996 | 143/935 | 12.4 (0–23) | 94.3 (92.5,95.6) | 89.2 (87.0,91.1) | 83.2 (80.7,85.6) | 1.8 (1.5–2.2) | < 0.001 |
* Number of revisions/number of total operations; **survivorship obtained via Kaplan-Meier analysis; HR = hazard ratio, according to Cox proportional hazards model (adjusted by sex and age); Duracon™, Stryker, Mahwah, NJ, USA; PFC® Sigma®, DePuy Orthopaedics Inc, Warsaw, IN, USA; Miller-Galante II, Zimmer, Warsaw, IN, USA; Porous Coated Anatomic (PCA®)/modular, Stryker, Mahwah, NJ, USA.